No more soda or candy with food stamps in these states: SNAP rule change explained
It is is part of the Donald Trump government's push towards 'Make America Healthy Again' (MAHA). The waivers will change the statutory definition of food for purchase for Supplemental Nutrition Assistance Programs (SNAP).
'It is incredible to see so many states take action at this critical moment in our nation's history and do something to begin to address chronic health problems. President Trump has changed the status quo, and the entire cabinet is taking action to Make America Healthy Again. At USDA, we play a key role in supporting Americans who fall on hard times, and that commitment does not change. Rather, these state waivers promote healthier options for families in need,' Rollins said.
Also Read | Trump, Coke and the Sugar Cartel
'For years, SNAP has used taxpayer dollars to fund soda and candy—products that fuel America's diabetes and chronic disease epidemics,' Kennedy noted, adding, 'These waivers help put real food back at the center of the program and empower states to lead the charge in protecting public health. I thank the governors who have stepped up to request waivers, and I encourage others to follow their lead. This is how we Make America Healthy Again.'
What does the new SNAP rule mean
Earlier SNAP recipients could buy anything with the food stamps except alcohol, tobacco, hot and prepared foods, and personal care products.
Rollins, meanwhile, said that 20 percent of SNAP dollars are spent on sugary drinks, salty snacks, pre-packaged desserts, and sugary treats. 'The number one purchase by SNAP recipients is sugary drinks,' she said.
Which states signed the SNAP waiver
The states which had signed this waiver today are West Virginia, Florida, Colorado, Louisiana, Oklahoma, and Texas. Previously, Nebraska, Iowa, Indiana, Arkansas, Idaho, and Utah had signed the waivers.
This takes the total to 12 states. The new waivers will go into effect in 2026.
FDA Commissioner Marty Makary, meanwhile, expressed hope that all 50 states would sign the waiver. 'I hope to see all 50 states join this bold commonsense approach. For too long, the root causes of our chronic disease epidemic has been addressed with lip service only. It's time for powerful changes to our nation's SNAP program. The goal is simple—reduce mass suffering from diabetes, obesity, and other long term medical conditions. I applaud the leadership of Secretaries Rollins and Kennedy, and President Trump in going bold,' he said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
an hour ago
- Economic Times
Novo Nordisk CEO warns of layoffs as Wegovy challenge heats up
Synopsis Novo Nordisk warned of ongoing competition from copycat versions of its obesity drug Wegovy and signaled possible layoffs due to slowing sales growth, especially in the U.S. The Danish drugmaker, which lost $95 billion in market value after cutting full-year forecasts, said over one million Americans still use compounded GLP-1 drugs despite a U.S. ban. Reuters Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could face layoffs as it battles rising pressure from main U.S. rival Eli Lilly, the Danish drugmaker warned on Wednesday. Novo, which became Europe's most valuable company worth $650 billion last year on booming sales of Wegovy, is facing a pivotal moment as the medicine loses market share and sees sales growth slow, especially in the United States. It has warned of far slower growth this year - in part due to compounders who have been allowed to make copycat medicines based on the same ingredients as Wegovy due to shortages. Novo cut its full-year sales and profit forecasts last week, wiping $95 billion off its market value since. The shares were down 3.4% at 1350 GMT. The slide is a huge and abrupt turnaround for the firm that has been one of the world's hottest investment stories, which led to a rapid expansion of manufacturing and sales capacity. Now the firm is eyeing potential cost-cutting measures. "We probably won't be able to avoid layoffs," outgoing CEO Lars Fruergaard Jorgensen told Danish broadcaster DR. "When you have to adjust a company, there are some areas where you have to have fewer people, some (areas) where you have to be smaller." He added, though, that any decision on layoffs would be in the hands of the incoming CEO, company veteran Maziar Mike Doustdar, who takes over on Thursday. On a media call, Jorgensen said the market for copycat versions of Wegovy's class of drugs - known as GLP-1 receptor agonists - was of "equal size to our business" and compounded versions of Wegovy were sold at a "much lower price point". In May, the company said it expected many of the roughly one million U.S. patients using compounded GLP-1 drugs to switch to branded treatments after a U.S. Food and Drug Administration ban on compounded copies of Wegovy took effect on May 22, and it expected compounding to wind down in the third quarter. However, finance chief Karsten Munk Knudsen said on Wednesday that more than one million U.S. patients were still using compounded GLP-1s and that Novo's lowered outlook has "not assumed a reduction in compounding" this year. "The obesity market is volatile," Knudsen told analysts when asked under what circumstances the company could see negative growth in the last six months of the year. The low end of Novo's new full-year guidance range would be for "unforeseen events", such as stronger pricing pressure in the U.S. than forecast, he said. The lower end of the range would imply sales around 150 billion Danish crowns ($23 billion) in the second half of 2025, compared with 157 billion in the same period last year. ENCOURAGING PRESCRIPTION DATA Knudsen reiterated that the company was pursuing multiple strategies, including lawsuits against compounding pharmacies, to halt unlawful mass compounding. Jorgensen said the company was encouraged by the latest U.S. prescription data for Wegovy. While the drug was overtaken earlier this year by rival Lilly's Zepbound in terms of U.S. prescriptions, that lead has narrowed in the past month. Second-quarter sales of Wegovy rose by 36% in the U.S. and more than quadrupled in markets outside the U.S. compared to a year ago, Novo said. While Wegovy's U.S. pricing held steady in the quarter, the company expected deeper erosion in the key U.S. market in the second half, due to a greater portion of sales expected from the direct-to-consumer or cash-pay channel, as well as higher rebates and discounts to insurers, Knudsen said. He said Novo was expanding its U.S. direct-to-consumer platform, NovoCare, launched in March, and may need to pursue similar "cash sales" directly to patients, outside of insurance channels, in some markets outside the United States. COST CUTS The company reiterated its full-year earnings expectations on Wednesday after last week's profit warning. Jorgensen said Novo was acting to "ensure efficiencies in our cost base" as the company announced it would terminate eight R&D projects. "There seems to be a larger R&D clean-out than usual, but we do not know if this reflects a strategic re-assessment or just a coincidence," Jefferies analysts said in a note. Investors have questioned whether Novo can stay competitive in the booming weight-loss drug market. Several equity analysts have cut their price targets and recommendation on the stock since last week. Shares in Novo plunged 30% last week - their worst weekly performance in over two decades. Sales rose 18% in the second quarter to 76.86 billion Danish crowns, below analysts' initial expectations.
Mint
4 hours ago
- Mint
NIH Grant Cuts Arent Saving Money. Theyre Wasting It.
(Bloomberg Opinion) -- The Trump administration's waves of massive cuts to funding at the National Institutes of Health are framed as a recasting of research priorities and a way to save taxpayer money. Another way to frame it is an exercise in massive waste. In terminating nearly 750 NIH grants over the past two months, the government dumped years of investment down the drain. The unceremonious end to those projects means we won't know the answers to studies that intended to improve the health of Americans. According to a Bloomberg Opinion analysis(1), Health and Human Services data show that some $373 million had already been spent on the 242 discontinued R01 grants, an NIH award that is considered critical to launching a successful career. Researchers tend to get that chunk of funding — typically a sizable amount that supports their work for 3 to 5 years — after they've done a few years of preliminary work. It's all geared toward asking a big scientific question. Our analysis doesn't include the untold number of NIH grants at Harvard University affected by the administration's $2.2 billion federal funding freeze this week — a punishment for refusing to comply with the government's long list of demands. But even if those funds are eventually restored, the disruption risks derailing studies related to ALS, tuberculosis and many other health conditions. Funding was pulled just as some of these projects were getting off the ground, while others were rounding into their last year of funding — a point where enough data would finally be collected to offer concrete results. Our analysis found that nearly 40% of the canceled R01 grants supported research that had yet to produce findings, meaning all of the agency's prior investments won't benefit the public. Take, for example, the abrupt end to Washington University of St. Louis professor Jeremy Goldbach's five-year grant to test the first evidence-backed intervention intended to help teachers, administrators and social workers support LGBTQ youth. A little over three years in, Goldbach had collected a massive amount of data from 20 schools — thousands of students had participated. But without his last rounds of funding, he won't be able to track the program's efficacy at the last four schools needed for the results to be statistically meaningful. That's more than $2.1 million that NIH already spent on the project down the drain, all because the government pulled the last few hundred thousand. (Goldbach's grant was one of many caught up in a sweep of cuts related to President Trump's gender ideology executive order.) But the loss goes beyond that. Goldbach's project built off years of earlier work. Before getting to the point where a review panel of more than two dozen experts felt the concept was promising enough to merit a large-scale study, the researcher had to design and test it. That work was supported by two earlier awards from NIH and financial help from foundations, which together amounted to nearly $900,000 in investment in the project. Moreover, about 15 people's jobs are on the line between the loss of this funding and around seven other terminated grants for studies that Goldbach is a collaborator on. At the other end of the spectrum, Northwestern University professor Michelle Birkett's $3.8 million grant was ended in the first of its five years. The funding was awarded to understand —and ultimately address — disparities in HIV transmission and substance use among gay men and transgender women. Although only a fraction of that promised money had been spent, Birkett had invested years of work into designing and securing funding for the study and had already recruited a community board across each of the five cities where it was poised to launch. Countless stories of similarly needless waste — research interrupted midstream and sidelined careers— live behind the HHS's long list of canceled funding. That translates into a massive number of health insights the public simply won't know about — yet had already paid to support. So many of those unanswered questions centered on prevention: How can we encourage simple changes that could have a big impact on the physical and mental health of Americans — and ultimately save the health care system money? For example, a cluster of projects devoted to improving uptake of the HPV vaccine, which has stalled in recent years, was among the research that recently lost funding. Not enough adolescents are getting the shots despite a growing body of data showing its ability to prevent deaths from cervical cancer in women and potentially lower the rates of head and neck, anal, penile, vaginal and vulvar cancers. Some of those HPV vaccine studies were well underway but, as with Goldbach's project, had yet to enroll enough volunteers to yield meaningful data on how to convince people to get the shot. Ultimately, that doesn't just waste the taxpayer money already spent on those grants; it could also cost the health care system later, in the form of otherwise preventable cancer cases. Abandoning these projects is far from an exercise in efficiency, as the Trump administration likes to tout. A more accurate word to sum up what's happening with these cuts would be: nonsensical. More From Bloomberg Opinion: Want more Bloomberg Opinion? OPIN GO. Or subscribe to our daily newsletter. (1) Bloomberg Opinion analyzed 748 terminated NIH grants from the HHS TAGGS data as of April 16. We merged in additional information about each grant, including the project start date and the number of associated publications, from the NIH RePORTER database. The length of each study is the time between the project's beginning and the grant termination date, which we visualize for three of the most common award types: R01, U01 and U54 grants. The funding already spent on R01s is calculated from the 'total amount expended' field in the HHS data. This column reflects the personal views of the author and does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners. Lisa Jarvis is a Bloomberg Opinion columnist covering biotech, health care and the pharmaceutical industry. Previously, she was executive editor of Chemical & Engineering News. Carolyn Silverman is a data journalist for Bloomberg Opinion. She previously served as a data scientist for the University of Chicago Crime Lab and Education Lab. More stories like this are available on
Hindustan Times
5 hours ago
- Hindustan Times
Kratom rise sparks concerns over addiction amid RFK Jr's 7-OH crackdown; What is it and how it impacts your health
Kratom has gained popularity following a viral TikTok video and Health and Human Services (HHS) Secretary Robert F. Kennedy Jr's recent press conference. Kratom-containing products are sold all over the country in gas stations, alcohol stores, and smoke shops.(X@LuLFo9) Kratom-containing products are sold all over the country in gas stations, alcohol stores, and smoke shops. They are available in three forms: beverages, capsules, and powder and some are even available in brightly colored packaging. Medical specialists believe kratom is highly addictive and gives similar effects like opioids and opiates. USA TODAY recently surveyed over 20 people who were severely addicted to kratom, leading to terrible outcomes. Meanwhile, several people on social raised an alarm over the usage of Kratom, claiming its adverse affects on health. 'WARNING: 'Feel Free' isn't as safe as it sounds. This kratom-based drink is being sold as a natural energy boost — but it's linked to addiction, liver damage, and even death,' one person claimed on X expressing worries over Kratom use. "Stay AWAY from the "herbal" drink, Feel Free. Unless you want to walk right into ADDICTION! It is suppose to be sold to people who are 21 and you can easily get it at any gas station. It has an UNREGULATED ingredient called kratom," another said. What we know about RFK Jr.'s crackdown on 7-OH In his briefing, RFK Jr. discussed the steps the government will take in reaction to a 'dangerous' synthetic opioid produced from kratom. 'Today, we're taking action on 7-OH as a critical step in the fight against opioid addiction,' he said during a July 29 press conference. 'We will protect the health of our nation's youth as we advance our mission to Make America Healthy Again.' The FDA issued this proposal after conducting an extensive medical and scientific investigation, and it is one of numerous measures to deal with the agency's concerns about the growing accessibility and usage of 7-OH opioid medications. There are no FDA-approved 7-OH medications, 7-OH is not allowed in dietary supplements, and 7-OH cannot be added to ordinary meals. Also Read: Who is Peter Alt? Long Island fire chief fired for hurling abuses, shouting at 10-year-old girl in crisis What is Kratom and how it is different from 7-OH Kratom is a plant product that is found in Southeast Asia. It's frequently sold as a herbal supplement that improves relaxation and increases vitality. Kratom refers to the complete plant substance, whereas 7-OH, which is abbreviated for 7-Hydroxymitragynine, is a chemical byproduct of kratom. Some products are manufactured from the entire kratom plant, while others are prepared with high amounts of 7-OH. Products advertised with 7-OH are often stronger and have recently come under scrutiny from the FDA. Kratom, according to Dr. Lief Fenno, chair of the American Psychiatric Association Council on Addiction Psychiatry, has managed to get away from scrutiny because it doesn't connect with brain receptors like heroin and morphine.
